JSSH(SZ:000518) Bei Ke Cai Jing·2025-05-08 03:52Core Viewpoint - Jiangsu Sihuan Biological Co., Ltd. has been placed under delisting risk warning due to its poor performance in 2024, leading to a significant drop in stock price and market capitalization [1][2]. Financial Performance - The company reported a revenue of 204 million yuan in 2024, a year-on-year decline of 13.55% [2]. - The net profit attributable to shareholders was -109 million yuan, a substantial decrease of 46.13% year-on-year [2]. - Cumulatively, the company has incurred losses of nearly 270 million yuan over the past four years, with a loss of over 100 million yuan in 2024 alone [2]. Market Challenges - Increased pressure from centralized drug procurement and intensified industry competition have significantly impacted the company's sales [3]. - The company's core products have seen a substantial decline in market share due to price reductions and competition from generic drugs [3]. Research and Development - The company has been increasing its R&D personnel from 16 in 2020 to 37 in 2024, with R&D expenses growing by 31.09% year-on-year in Q1 2025 [3][4]. - Despite the increase in R&D investment, the total amount remains below 30 million yuan, which is insufficient to develop competitive new products [4]. Operational Issues - The company's diversification into landscaping and ecological projects has not improved performance and has instead become a burden due to asset impairment losses [5]. - The company has faced significant challenges related to its actual controller, leading to legal and financial repercussions that have further eroded investor confidence [6][7]. Legal and Regulatory Challenges - The company has been subject to administrative penalties and market bans due to false disclosures, resulting in ongoing litigation with investors totaling approximately 27.32 million yuan [7]. - The recent changes in control and ongoing legal issues have severely damaged the company's reputation in the capital market [7].